Zydus Cadila gets USFDA nod for generic gout attacks drug- Colchicine
The tablets, "will be manufactured at the group's formulations manufacturing facility at SEZ, Ahmedabad," it said.
The product is the generic version of Colcyrs tablets in the same strength, it added.
The tablets, "will be manufactured at the group's formulations manufacturing facility at SEZ, Ahmedabad," it said.
The drug is used to prevent or treat attacks of gout, a condition caused by high uric acid levels in the blood. The medication is also used to treat familial Mediterranean fever.
The group now has 223 approvals and has so far filed over 330 abbreviated new drug applications (ANDAs) since the commencement of its filing process, Zydus Cadila said.
Read Also: Zydus Cadila gets USFDA nod to market Clobetasol Propionate cream for skin treatment
New Delhi: Drug firm Zydus Cadila Thursday said it has received a tentative nod to market generic Colchicine tablets used for prevention and treatment of gout attacks in US market. The company has received the tentative approval from the United States Food and Drug Administration (USFDA) to market Colchicine tablets USP in the strength of 0.6 mg, Zydus Cadila said in a statement.
The product is the generic version of Colcyrs tablets in the same strength, it added.
The tablets, "will be manufactured at the group's formulations manufacturing facility at SEZ, Ahmedabad," it said.
The drug is used to prevent or treat attacks of gout, a condition caused by high uric acid levels in the blood. The medication is also used to treat familial Mediterranean fever.
The group now has 223 approvals and has so far filed over 330 abbreviated new drug applications (ANDAs) since the commencement of its filing process, Zydus Cadila said.
Read Also: Zydus Cadila gets USFDA nod to market Clobetasol Propionate cream for skin treatment
AhmedabadcolchicineColchicine goutColchicine tablets USPDrug firmgeneric Colchicine tabletsgout medicineSEZtreatment of gout attacksUnited States Food and Drug AdministrationUS marketUSFDAZydus Cadila
Source : PTIMedical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here
Next Story
NO DATA FOUND
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd